{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:40:32Z","timestamp":1761162032044,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4733,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,2]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objective<\/jats:bold>\n                    . To assess the interaction between therapeutic dosages of ropinirole and\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa plus a decarboxylase inhibitor administered at steady state in patients with Parkinson's disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    . Open, 6\u2010week, overlap trial with random allocation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients<\/jats:bold>\n                    . Thirty patients with Parkinson's disease not previously treated with dopamine agonists, of whom 28 produced evaluable pharmacokinetic data for ropinirole and 23 for\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Intervention.<\/jats:bold>\n                    Group A (14 patients) received\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa for weeks 1\u20135 and ropinirole in increasing increments for weeks 2\u20136; group B (16) received ropinirole for weeks 1\u20135 and\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa for weeks 5 and 6.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results.<\/jats:bold>\n                    Primary end points were AUC\n                    <jats:sub>0\u20138<\/jats:sub>\n                    and C\n                    <jats:sub>max<\/jats:sub>\n                    for ropinirole, and AUC\n                    <jats:sub>0\u20138<\/jats:sub>\n                    , AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    , and C\n                    <jats:sub>max<\/jats:sub>\n                    for\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa. Secondary end points were T\n                    <jats:sub>max<\/jats:sub>\n                    for ropinirole, and T\n                    <jats:sub>max<\/jats:sub>\n                    and half\u2010life for\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa. Coadministration with\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa at steady state did not affect rate or extent of availability of ropinirole: point estimates of the geometric mean ratio for ropinirole plus\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa compared with ropinirole alone for both C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0\u20138<\/jats:sub>\n                    approximated to unity. The small (16%) increase in peak concentrations of\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa on administration with ropinirole is unlikely to be of clinical consequence, as peak concentrations of\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa are typically highly variable.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    . There are no pharmacokinetic grounds for adjusting dosages of either ropinirole or\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa when given in combination.\n                  <\/jats:p>","DOI":"10.1592\/phco.19.3.150.30927","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T10:17:13Z","timestamp":1083061033000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L\u2010Dopa in Patients with Parkinson's Disease"],"prefix":"10.1002","volume":"19","author":[{"given":"Anne C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almisbah","family":"Beerahee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Citerone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Cyronak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry J.","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Lopez\u2010Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarosh D.","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Lennox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91146-1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199012000-00007"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-83-4-456"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.29.9_Part_1.1253"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.826"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.9.1034"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90603-Y"},{"issue":"2","key":"e_1_2_1_9_2","first-page":"240P","article-title":"Linear pharmacokinetics of ropinirole in patients with Parkinsons disease","volume":"45","author":"Taylor A.C.","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198713030-00002"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00236a004"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(24)07117-9","article-title":"Metabolism of carbidopa [l\u2010\u03b1\u2010Hydrazino\u20103,4\u2010dihydroxy\u2010\u03b1\u2010methylhydrocinnamic acid monohydrate], an aromatic amino acid decarboxylase inhibitor, in the rat, dog, Rhesus monkey, and man","volume":"2","author":"Vickers S.","year":"1974","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_13_2","first-page":"840","article-title":"In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole","volume":"25","author":"Bloomer J.C.","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.t01-1-00704.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.10.1288"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02913.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197611050-00001"},{"key":"e_1_2_1_18_2","first-page":"556P","article-title":"Population pharmacokinetics of ropinirole in patients with Parkinsons disease","volume":"43","author":"Beerahee A.","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.3.150.30927","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.3.150.30927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:46:30Z","timestamp":1761065190000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.3.150.30927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["10.1592\/phco.19.3.150.30927"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.3.150.30927","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1999,2]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}